Seeking Alpha

Sangamo BioSciences (SGMO -3.7%) stabilizes after a volatile opening this morning, albeit lower,...

Sangamo BioSciences (SGMO -3.7%) stabilizes after a volatile opening this morning, albeit lower, after announcing the presentation of encouraging new clinical data from its program to develop a ZFP Therapeutic for HIV/AIDS. The data, which demonstrates that SB-728-T treatment results in a reduction in the HIV reservoir in HIV-infected subjects, is being presented at the 16th Annual Meeting of the American Society of Gene and Cell Therapy. 
Comments (2)
  • Giovanni di Maggio
    , contributor
    Comments (46) | Send Message
     
    Good chance to buy some cheap shares. Results for HIV are good and this is by far not the only drug in the pipeline. As with all biotechs, patience is required.
    15 May 2013, 02:24 PM Reply Like
  • robo10311
    , contributor
    Comment (1) | Send Message
     
    Any ideas why the stock has traded off with the positive clinical news this morning?
    15 May 2013, 03:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|